Medicine and Dentistry
Human Immunodeficiency Virus
98%
COVID-19
78%
Patient
75%
Infection
46%
Severe Acute Respiratory Syndrome Coronavirus 2
39%
Drug Resistance
27%
Reverse-Transcriptase Inhibitor
18%
Kidney Function
17%
Therapeutic Procedure
17%
Electronic Health Record
16%
Predictor
16%
Cohort Study
16%
Hospital Mortality
16%
T-Helper Cell
16%
Survival
15%
Antiretroviral Therapy
14%
Omicron Coronavirus Variant
13%
Fibrosis
13%
Colistimethate
13%
Cefiderocol
13%
Acute Kidney Injury
13%
Postcovid Syndrome
13%
Elderly Patient
13%
Cholecystitis
13%
Long-Term Care
13%
Valaciclovir
13%
Human Immunodeficiency Virus Infection
13%
Incidence
11%
Highly Active Antiretroviral Therapy
11%
Chemotherapeutic Agent
10%
Drug
10%
Follow up
10%
Diagnosis
10%
Coronary Artery Disease
10%
Ribavirin
10%
Analysis
9%
Paritaprevir
9%
Ombitasvir
9%
Ritonavir
9%
Prevalence
9%
Proteinase
9%
Aptitude
9%
Proportional Hazards Model
8%
Person
8%
Liver Fibrosis
8%
Cells
8%
Inpatient
8%
Association
7%
Mortality Rate
7%
Proteinase Inhibitor
7%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Drug Resistance
45%
Ritonavir
31%
Hepatitis C Virus
30%
Ribavirin
23%
Prevalence
22%
Clinical Trial
22%
Infection
20%
Hepatitis C Virus Genotype 1
20%
Tenofovir
19%
RNA Directed DNA Polymerase Inhibitor
18%
Paritaprevir
18%
Ombitasvir
18%
Proteinase Inhibitor
17%
RNA Directed DNA Polymerase
16%
Liver Cirrhosis
15%
Dasabuvir
15%
Nirmatrelvir
13%
Ritonavir
13%
Molnupiravir
13%
Hypertransaminasemia
13%
Emtricitabine Plus Tenofovir Alafenamide
13%
Bictegravir
13%
Fibrosis
13%
Dengue
13%
Colistimethate
13%
Acinetobacter Baumannii
13%
Valaciclovir
13%
Drug
13%
HIV Therapy
11%
Adverse Event
11%
Proteinase
9%
Liver Fibrosis
8%
Mixed Infection
8%
Hepatitis C Virus Genotype 4
8%
Human Immunodeficiency Virus Type 1 Subtype C
6%
Cell Culture
6%
Incidence
6%
Diseases
6%
Combination Therapy
6%
Virus RNA
6%
Observational Study
5%
Hypernatremia
5%
RNA
5%
Prospective Cohort Study
5%
Immunology and Microbiology
Human Immunodeficiency Virus
79%
Drug Resistance
34%
Hepatitis C Virus
32%
Mutation
24%
Cladistics
19%
Tenofovir
19%
Prevalence
16%
Reverse Transcriptase
14%
Lymphocyte
13%
Fitness
13%
Acinetobacter Baumannii
13%
COVID-19
10%
Human Immunodeficiency Virus Infection
9%
CD4
9%
Evolution
9%
Age
8%
T-Helper Cell
8%
Liver
8%
Time
8%
NS5A Inhibitors
7%
CD4 Lymphocyte Count
7%
NS5A
7%
Human Immunodeficiency Virus Type 1 Subtype C
6%
Cell Culture
6%
Comorbidity
6%
Incidence
6%
RNA Virus
6%
Colistin
6%
Platelet
5%
Association
5%
C-Reactive Protein
5%
Learning
5%
Hospital Mortality
5%
Genotype
5%
Hepatitis C Virus Genotype 1
5%
